Archives
Monthly Archives
Categories
- Conflict of Interest Regulation
- Consumer Driven Health Care
- Drug Importation and Price Controls
- Drug and Medical Device Litigation
- FDA Regulation & Medical Innovation
- Intellectual Property Rights and Innovation
- Medicare and Medicaid
- Personalized Medicine
- Pharmaceutical Advertising, Communication, and Labeling
- Value of Medicine
keep in touch     |
Our Research
Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials
by Avik Roy, April 2012
Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research
by Tomas J. Philipson, Eric Sun, June 2011
How Conflict-of-Interest Rules Endanger Medical Progress and Cures
by Richard A. Epstein, October 2010
Cost of Caution: The Impact on Patients of Delayed Drug Approvals
by Tomas J. Philipson, Eric Sun, June 2010
In the Wake of Wyeth v. Levine: Making the Case for FDA Preemption and Administrative Compensation
by James R. Copland, Paul Howard, March 2009
MORE REPORTS >>
by Avik Roy, April 2012
Blue Pill or Red Pill: The Limits of Comparative Effectiveness Research
by Tomas J. Philipson, Eric Sun, June 2011
How Conflict-of-Interest Rules Endanger Medical Progress and Cures
by Richard A. Epstein, October 2010
Cost of Caution: The Impact on Patients of Delayed Drug Approvals
by Tomas J. Philipson, Eric Sun, June 2010
In the Wake of Wyeth v. Levine: Making the Case for FDA Preemption and Administrative Compensation
by James R. Copland, Paul Howard, March 2009
MORE REPORTS >>
Blogroll
American Council on Science and Health
in the Pipeline
Drugwonks
Pharmalot
Reason – Peter Suderman
WSJ Health Blog
The Hill’s Healthwatch
Forbes ScienceBiz
The Apothecary
EyeOnFDA
KevinMD
Marginal Revolution
Megan McArdle
LifeSci VC
Critical Condition
EconLog
In Vivo Blog
PharmaGossip
Pharma Strategy Blog
Drug Discovery Opinion
